Q1 2024 EPS Estimates for OptimizeRx Co. Lowered by Analyst (NASDAQ:OPRX)

OptimizeRx Co. (NASDAQ:OPRX) – Research analysts at William Blair lowered their Q1 2024 EPS estimates for shares of OptimizeRx in a report released on Tuesday, April 16th. William Blair analyst R. Daniels now forecasts that the company will post earnings per share of ($0.34) for the quarter, down from their previous estimate of ($0.29). The consensus estimate for OptimizeRx’s current full-year earnings is ($0.57) per share. William Blair also issued estimates for OptimizeRx’s Q2 2024 earnings at ($0.21) EPS, Q3 2024 earnings at ($0.04) EPS, Q4 2024 earnings at $0.06 EPS and FY2024 earnings at ($0.51) EPS.

Several other brokerages have also issued reports on OPRX. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 target price on shares of OptimizeRx in a research note on Monday, April 1st. Stifel Nicolaus reissued a “buy” rating and set a $13.00 price objective on shares of OptimizeRx in a research note on Monday, April 1st. JMP Securities reissued a “market outperform” rating and set a $15.00 price objective on shares of OptimizeRx in a research note on Tuesday. Finally, Barclays initiated coverage on shares of OptimizeRx in a research note on Wednesday, January 3rd. They set an “equal weight” rating and a $15.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $15.86.

OptimizeRx Trading Down 0.3 %

Shares of NASDAQ OPRX opened at $9.32 on Thursday. The firm has a market capitalization of $169.44 million, a PE ratio of -9.23 and a beta of 0.98. OptimizeRx has a 1 year low of $6.92 and a 1 year high of $16.65. The firm’s 50-day moving average is $13.24 and its 200-day moving average is $11.96.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Captrust Financial Advisors lifted its stake in OptimizeRx by 248.8% in the second quarter. Captrust Financial Advisors now owns 1,287 shares of the company’s stock valued at $35,000 after buying an additional 918 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of OptimizeRx in the first quarter valued at approximately $52,000. UBS Group AG raised its holdings in shares of OptimizeRx by 290.0% in the third quarter. UBS Group AG now owns 1,997 shares of the company’s stock valued at $29,000 after purchasing an additional 1,485 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of OptimizeRx by 215.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company’s stock valued at $31,000 after purchasing an additional 1,462 shares during the last quarter. Finally, Cetera Trust Company N.A acquired a new stake in shares of OptimizeRx in the fourth quarter valued at approximately $77,000. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.